Amneal Pharmaceuticals, Inc. - Class A Common Stock, par value $0.01 (AMRX)

Historical Holders from Q2 2018 to Q4 2025

Type / Class
Equity / Class A Common Stock, par value $0.01
Symbol
AMRX on Nasdaq
Shares outstanding
315,976,000
Price per share
$12.60
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
150,648,996
Total reported value
$1,508,361,145
% of total 13F portfolios
0%
Share change
+7,749,626
Value change
+$80,964,118
Number of holders
244
Price from insider filings
$12.60
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Amneal Pharmaceuticals, Inc. - Class A Common Stock, par value $0.01 (AMRX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Patel Tushar Bhikhubhai 16% $363,365,003 48,578,209 Patel Tushar Bhikhubhai 14 Mar 2025
Patel Chintu 8.2% $259,359,420 25,910,032 Patel Chintu 03 Oct 2025
Patel Dipan 7.6% -1.2% $238,528,210 23,828,992 0% Patel Dipan 03 Oct 2025
Patel Chirag K. 7.1% $179,439,606 22,180,421 Patel Chirag K. 06 Aug 2025
Mahesh Akram 6.6% $153,779,517 20,558,759 Akram Mahesh 31 Mar 2025
VANGUARD GROUP INC 5% $117,905,198 15,762,727 The Vanguard Group 31 Mar 2025
As of 30 Sep 2025, Amneal Pharmaceuticals, Inc. - Class A Common Stock, par value $0.01 (AMRX) has 244 institutional shareholders filing 13F forms. They hold 150,648,996 shares. of 315,976,000 outstanding shares (48%) .

Top 25 institutional shareholders own 37% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
VANGUARD GROUP INC 5.7% 17,954,973 +2.3% 0% $179,729,279
BlackRock, Inc. 4.5% 14,073,653 +16% 0% $140,877,267
Rubric Capital Management LP 3.9% 12,334,941 +5.3% 1.7% $123,472,759
TPG GP A, LLC 3.9% 12,328,767 0% 6.7% $123,410,958
CITADEL ADVISORS LLC 1.8% 5,729,299 +1.9% 0.05% $57,350,283
DIMENSIONAL FUND ADVISORS LP 1.7% 5,431,134 +2.5% 0.01% $54,360,826
Nantahala Capital Management, LLC 1.3% 4,224,564 -3.3% 2.6% $42,287,886
GEODE CAPITAL MANAGEMENT, LLC 1.3% 4,034,633 +7.3% 0% $40,393,130
STATE STREET CORP 1.3% 3,973,748 +1.5% 0% $39,777,217
NEUBERGER BERMAN GROUP LLC 1.2% 3,716,075 -0.19% 0.03% $37,176,822
MORGAN STANLEY 1.1% 3,503,081 +40% 0% $35,065,847
MILLENNIUM MANAGEMENT LLC 1.1% 3,332,751 -34% 0.03% $33,360,838
Nuveen, LLC 1% 3,225,232 +21% 0.01% $32,284,572
ACADIAN ASSET MANAGEMENT LLC 0.82% 2,590,522 -2.7% 0.05% $25,913,000
GOLDMAN SACHS GROUP INC 0.78% 2,460,214 +10% 0% $24,626,742
BlackBarn Capital Partners LP 0.69% 2,189,452 -36% 7.2% $21,916,415
Assenagon Asset Management S.A. 0.68% 2,150,041 +187% 0.03% $21,521,910
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.66% 2,082,814 +14% 0% $20,848,968
Qube Research & Technologies Ltd 0.56% 1,757,653 -8% 0.02% $17,594,107
Invesco Ltd. 0.53% 1,685,386 +44% 0% $16,870,714
NORTHERN TRUST CORP 0.52% 1,628,272 +1.1% 0% $16,299,002
D. E. Shaw & Co., Inc. 0.5% 1,565,211 +69% 0.01% $15,667,762
ROYAL BANK OF CANADA 0.49% 1,538,938 +0.02% 0% $15,405,000
AMERIPRISE FINANCIAL INC 0.47% 1,471,636 -14% 0% $14,731,076
UBS Group AG 0.46% 1,445,801 -8.7% 0% $14,472,468

Institutional Holders of Amneal Pharmaceuticals, Inc. - Class A Common Stock, par value $0.01 (AMRX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q4 4,764,148 $60,051,079 +$32,338,912 $12.60 11
2025 Q3 150,648,996 $1,508,361,145 +$80,964,118 $10.01 244
2025 Q2 141,656,835 $1,146,033,099 +$54,531,142 $8.09 237
2025 Q1 134,631,456 $1,128,246,067 +$84,513,755 $8.38 232
2024 Q4 125,924,024 $997,296,789 -$136,424,861 $7.92 194
2024 Q3 142,604,811 $1,186,537,394 +$32,304,784 $8.32 180
2024 Q2 138,637,695 $880,361,225 +$192,128,358 $6.35 179
2024 Q1 108,100,411 $655,086,509 -$6,545,489 $6.06 173
2023 Q4 109,241,884 $663,112,026 +$52,701,039 $6.07 151
2023 Q3 101,896,343 $430,042,448 +$19,693,333 $4.22 141
2023 Q2 97,368,877 $301,754,419 +$4,221,215 $3.10 122
2023 Q1 96,883,833 $134,657,443 -$8,205,387 $1.39 142
2022 Q4 101,876,885 $202,739,453 +$4,463,674 $1.99 155
2022 Q3 99,522,767 $201,053,119 -$1,681,376 $2.02 144
2022 Q2 99,362,374 $315,991,849 -$2,095,558 $3.18 140
2022 Q1 100,125,536 $417,146,539 -$2,779,055 $4.17 154
2021 Q4 100,743,592 $481,044,810 -$750,941 $4.79 148
2021 Q3 100,372,906 $535,260,080 +$2,515,423 $5.34 150
2021 Q2 99,933,342 $511,565,477 -$13,076,955 $5.12 153
2021 Q1 101,580,612 $683,525,934 +$24,752,974 $6.73 155
2020 Q4 99,489,363 $454,601,386 -$9,010,325 $4.57 128
2020 Q3 101,459,246 $393,634,017 -$1,370,007 $3.88 133
2020 Q2 101,691,059 $484,034,077 +$16,566,905 $4.76 131
2020 Q1 98,300,162 $342,039,040 -$17,271,636 $3.48 117
2019 Q4 101,152,211 $487,526,241 -$9,606,036 $4.82 116
2019 Q3 108,293,336 $314,077,694 -$45,957,076 $2.90 111
2019 Q2 105,380,317 $755,561,286 -$88,067,679 $7.17 116
2019 Q1 109,021,244 $1,544,805,998 -$98,023,386 $14.17 150
2018 Q4 116,187,735 $1,572,087,804 +$89,696,977 $13.53 157
2018 Q3 108,476,937 $2,407,193,089 +$282,716,887 $22.19 162
2018 Q2 97,469,656 $1,599,487,071 +$1,599,409,043 $16.41 163